Sage Bionetworks Announces Oncology Research Partnership with Pfizer
News Jan 18, 2010
Sage Bionetworks has announced a new research partnership with Pfizer, Inc. to build, analyze and exploit advanced network models of cancer.
Pfizer will provide research funding to Sage to analyze large, globally coherent datasets from Pfizer, Sage and the public domain. Through innovative network biology analysis Sage will use the genetic, molecular and clinical information to create predictive computational disease models. These models will help identify therapeutic targets for oncology drug development as well as aid in evaluating the efficacy and safety of drug development candidates.
“We continue to implement our partnering strategy as part of our larger mission to build a Commons where users can exploit the full potential of network analysis across multiple complex datasets.”
“Our collaboration with Pfizer will help develop more innovative and more effective disease models and in turn help define specific patient sub-populations most likely to respond to new therapies,” said Dr. Stephen Friend, President of Sage Bionetworks.
“We continue to implement our partnering strategy as part of our larger mission to build a Commons where users can exploit the full potential of network analysis across multiple complex datasets,” Dr. Friend added. “Data and models from the collaboration will become available in the Sage repository one year following the completion of the project expanding the datasets publicly available.”
Scientists at Tokyo Tech, Ricoh co. and The National Institute of Advanced Industrial Science and Technology have developed an ultra-low-power atomic clock (ULPAC) for small satellites to enable future communication systems beyond 5G. The proposed device outperforms the current industry standards in various benchmarks, such as size, stability, and power consumption.
With their ability to treat a wide a variety of diseases, spherical nucleic acids are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components. A team has developed a direct route to optimize these particles, bringing them one step closer to becoming a viable treatment option for numerous diseases, including cancer.READ MORE
A human pluripotent stem cell line has been engineered which contains two ‘suicide genes’ that induce cell death in all but the desired insulin-producing cells. This double fail-safe approach opens the door to creating safe cell-replacement therapies for people living with type 1 diabetes.READ MORE